Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, presents the results of a Phase I trial (NCT04720313) evaluating the efficacy of HBI0101, an anti-BCMA CAR T-cell therapy, for relapsed/refractory (R/R) multiple myeloma (MM). Dr Lebel highlights the promising results observed with this academic CAR-T product, with a response rate of 92% and high rates of measurable residual disease (MRD) negativity. Additionally, the safety profile was comparable to other CAR-T therapies. This study demonstrates the benefits of an academic CAR-T approach with more flexible eligibility criteria, potentially reaching patients with advanced disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
